In addition, EGFR mutations are also associated with an increase in the incidence of NSCLC BMs compared with EGFR wild-type group (odds ratio (OR) = 2.01; 95% CI, 1.56–2.59; p = 0.000) [8]. Here, EGFR is linked to non-small cell lung carcinoma.